PEB-Pacific Edge

[winner (n)]

Did I see the word PROFIT in the headline

[LoungeLizard]

I thought this comment was intriguing:

"The company is now focused on selective investments to drive commercial execution in the US."
 

[Pierre]

After many twists and turns on the US Medicare roller coaster a positive outcome from Novitas before year-end now seems almost inevitable.

Peter Meintjes has proved to be the right man to lead the company through the US dramas and combined with continuing growth in the APAC region, the trajectory for PEB is looking extremely good.

The SP continues to hover around 27-30cps and I cant help pondering where it might settle when the LCD decision we are anticipating is announced. I'm picking somewhere around 60c until the full financial benefit starts to be realised. Your thoughts?

[Poet]

After many twists and turns on the US Medicare roller coaster a positive outcome from Novitas before year-end now seems almost inevitable.

Peter Meintjes has proved to be the right man to lead the company through the US dramas and combined with continuing growth in the APAC region, the trajectory for PEB is looking extremely good.

The SP continues to hover around 27-30cps and I cant help pondering where it might settle when the LCD decision we are anticipating is announced. I'm picking somewhere around 60c until the full financial benefit starts to be realised. Your thoughts?

Agree with you Peter is a great person to have at the helm right now.

Also, we shouldn't overlook the Chief Commercial Officer James Vaughn who has serious form in commercialising this type of opportunity.

From GPT:


Proven diagnostic commercialization. Vaughn spent 17 years at Genomic Health, including seven as Chief Commercial Officer, where he helped build adoption of Oncotype DX into one of the world's most successful molecular diagnostics franchises.
Experience driving physician behavior change. Convincing urologists to replace or reduce invasive procedures with genomic testing is very similar to the challenge Cxbladder faces. He has already navigated that type of market transformation.
Strong urology network. During the development of Oncotype DX Prostate he built relationships with leading urologists and key opinion leaders, which can accelerate Cxbladder adoption.
Commercial payer expertise. Beyond Medicare, long-term growth depends on commercial insurers. Vaughn has extensive experience in reimbursement strategy and managed care, which should help expand private payer coverage.
Scaling sales execution. Pacific Edge created the new Chief Commercial Officer role specifically to focus on sales, marketing and market access. His role is to convert guideline inclusion and reimbursement into sustained test volume growth.
Track record of creating shareholder value. During his tenure leading commercial operations at Genomic Health, the growth of Oncotype DX contributed to the company's eventual US$2.8 billion acquisition by Exact Sciences. While that does not guarantee a similar outcome for Pacific Edge, it demonstrates experience in scaling a diagnostics business successfully.